Showing 6241-6250 of 7326 results for "".
- New CFO at Evolus, Inc.https://practicaldermatology.com/news/new-cfo-at-evolus-inc/2457744/Lauren Silvernail is the new Chief Financial Officer and Executive Vice President, Corporate Development at Evolus, Inc. Silvernail joins Evolus from Revance Therapeutics where she most recently served as Chief Financial Officer and Chief Business Officer. Prior to her time at Revance The
- FDA Approves Cimzia for Moderate to Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-cimzia-for-moderate-to-severe-plaque-psoriasis/2457747/The FDA has approved extending the label for UCB's Cimzia (certolizumab pegol) to include a new indication in adults with moderate to severe plaque psoriasis. Cimzia is indicated for the treatment of adults with moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy
- Severe AD Linked to CV Risk in Large Trialhttps://practicaldermatology.com/news/severe-ad-linked-to-cv-risk-in-large-trial/2457748/Eczema now joins the list of inflammatory conditions linked to cardiovascular risk. British researchers report that individuals with severe eczema may be at greater risk for heart attack, stroke and atrial fibrillation. Their study appears in the
- Rapamycin Lotion Reduces Facial Tumors Caused by Tuberous Sclerosishttps://practicaldermatology.com/news/rapamycin-lotion-reduces-facial-tumors-caused-by-tuberous/2457750/Rapamycin lotion significantly reduced the disfiguring facial tumors affecting more than 90 percent of people with tuberous sclerosis complex (TSC), researchers from The University of Texas Health Science Center at Houston (UTHealth) report. Findings of the multicenter, international stud
- Psoriatic Arthritis Awareness Project Launcheshttps://practicaldermatology.com/news/psoriatic-arthritis-awareness-project-launches/2457751/In recognition of Psoriatic Arthritis Action Month, the National Psoriasis Foundation (NPF), in collaboration with Novartis Pharmaceuticals Corporation, has premiered the Psoriatic Arthritis (PsA) Awareness Project. The PsA Awareness Project is a set of patient films that highlight the impo
- Skincare on Trial: Revision Introduces New Patient-Friendly Optionhttps://practicaldermatology.com/news/skincare-on-trial-revision-introduces-new-patient-friendly-option/2457752/Revision Skincare has introduced a collection of five comprehensive 45-day trial regimens they say are designed to address the needs of
- Dr. Daniel Siegel Joins MedX's Medical Advisory Boardhttps://practicaldermatology.com/news/dr-daniel-siegel-joins-medxs-medical-advisory-board/2457754/Daniel Siegel, MD, Clinical Professor of Dermatology at SUNY Downstate in Brooklyn, New York, and a former President of the American Academy of Dermatology has joined the Medical Advisory Board of MedX Health Corp. “Daniel’s academic and practical business experience is impres
- FDA Approves Lilly's Taltz for Label Update to Treat Psoriasis Involving the Genital Areahttps://practicaldermatology.com/news/fda-approves-lillys-taltz-for-label-update-to-treat-psoriasis-involving-the-genital-area/2457755/The FDA has approved a label update for Taltz (ixekizumab) injection 80 mg/mL to include data in psoriasis involving the genital area. Eli Lilly and Company's Taltz is the first treatment FDA approved for moderate-to-severe plaque psoriasis that includes such data in its label. Taltz was
- Biotin Supplements Caused Misleading Test Results, Almost Led to an Unnecessary Procedurehttps://practicaldermatology.com/news/biotin-supplements-caused-misleading-test-results-almost-led-to-an-unnecessary-procedure/2457758/A new case report in the Journal of the Endocrine Society documents how a patient's use of a biotin supplement, caused her to have clinically misleading test results, whic
- Castle Creek Pharmaceuticals Receives FDA Rare Pediatric Disease Designation for Diacerein 1% Ointment for EBhttps://practicaldermatology.com/news/castle-creek-pharmaceuticals-receives-fda-rare-pediatric-disease-designation-for-diacerein-1-ointment-for-eb/2457765/The FDA has granted rare pediatric disease designation for Castle Creek Pharmaceuticals' (CCP) diacerein 1% ointment (CCP-020) for the treatment of epidermolysis bullosa (EB). The safety and efficacy of CCP-020 is currently being evaluated in the DELIVERS study for the treatment of pat